Literature DB >> 11872041

The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour.

T Kamai1, K Arai, S Sumi, T Tsujii, M Honda, T Yamanishi, K-I Yoshida.   

Abstract

OBJECTIVE: To clarify the role of one of the downstream effectors of Rho (Rho-kinase) in testicular germ cell tumour (GCT) by quantifying mRNA expression for Rho-kinase in patients with this disease.
MATERIALS AND METHODS: The mRNA levels of the RhoA and Rho-kinase genes were analysed in surgical specimens of testicular GCT tissues from 57 consecutive Japanese patients, and in the corresponding non-tumour tissue originating from the same patient, using the polymerase chain reaction after reverse transcription. The expression levels of these genes were compared between the tissues and the relationship between their expression levels evaluated within tumours and with tumour stage. The difference in the expression levels of the mRNAs of RhoA and Rho-kinase genes were also assessed between tumours that were seminoma only and mixed tumours of seminoma and nonseminoma.
RESULTS: RhoA and Rho-kinase mRNAs were more abundant in tumour tissue than in non-tumour tissue (P < 0.01 and < 0.05, respectively). High RhoA and Rho-kinase mRNA expressions were related to tumour stage (P < 0.05 and < 0.01, respectively). The mRNA levels of RhoA and Rho-kinase in mixed tumours were higher than in tumours with seminoma only (P < 0.01 and < 0.05, respectively). There was a positive relationship between expression levels of mRNAs of RhoA and Rho-kinase in tumour tissues (P < 0.001).
CONCLUSIONS: These findings suggest that the RhoA/Rho-kinase pathway is involved in the progression of testicular GCT. This pathway might be a molecular target for new treatment strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872041     DOI: 10.1046/j.1464-4096.2001.01920.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells.

Authors:  Catharine A Street; Alissa A Routhier; Carrie Spencer; Ashley L Perkins; Katherine Masterjohn; Alexander Hackathorn; John Montalvo; Emily A Dennstedt; Brad A Bryan
Journal:  Int J Oncol       Date:  2010-11       Impact factor: 5.650

2.  The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

3.  Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients.

Authors:  Jie Fan; Li-Jie Ma; Shu-Jie Xia; Long Yu; Qiang Fu; Chao-Qun Wu; Xing-Hua Huang; Jian-Ming Jiang; Xiao-Da Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-14       Impact factor: 4.553

4.  Blocking Modification of Eukaryotic Initiation 5A2 Antagonizes Cervical Carcinoma via Inhibition of RhoA/ROCK Signal Transduction Pathway.

Authors:  Xiaojun Liu; Dong Chen; Jiamei Liu; Zhangtao Chu; Dongli Liu
Journal:  Technol Cancer Res Treat       Date:  2016-09-07

Review 5.  Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis.

Authors:  Catharine A Street; Brad A Bryan
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

6.  Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression.

Authors:  Carrie Spencer; John Montalvo; Sarah R McLaughlin; Brad A Bryan
Journal:  Cancer Genomics Proteomics       Date:  2011 Mar-Apr       Impact factor: 4.069

7.  Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.

Authors:  Pierre Morin; Cristina Flors; Michael F Olson
Journal:  Eur J Cell Biol       Date:  2009-06-09       Impact factor: 4.492

Review 8.  [Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].

Authors:  A Martinschek; C G Ruf; C Sparwasser; H U Schmelz
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

9.  A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion.

Authors:  Vijay Pralhad Kale; Jeremy A Hengst; Dhimant H Desai; Taryn E Dick; Katherine N Choe; Ashley L Colledge; Yoshinori Takahashi; Shen-Shu Sung; Shantu G Amin; Jong K Yun
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

10.  ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression.

Authors:  J Montalvo; C Spencer; A Hackathorn; K Masterjohn; A Perkins; C Doty; A Arumugam; P P Ongusaha; R Lakshmanaswamy; J K Liao; D C Mitchell; B A Bryan
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.